Pure Biologics Spólka Akcyjna

Warsaw Stock Exchange PUR.WA

Pure Biologics Spólka Akcyjna Dividend Yield on February 03, 2025: 0.00%

Pure Biologics Spólka Akcyjna Dividend Yield is 0.00% on February 03, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Pure Biologics Spólka Akcyjna 52-week high Dividend Yield is 0.00% on February 03, 2025, which is 0.00% below the current Dividend Yield.
Pure Biologics Spólka Akcyjna 52-week low Dividend Yield is 0.00% on February 03, 2025, which is 0.00% below the current Dividend Yield.
Pure Biologics Spólka Akcyjna average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

Warsaw Stock Exchange: PUR.WA

Pure Biologics Spólka Akcyjna

CEO	Dr. Filip Jelen M.B.A., Ph.D.
IPO Date	Dec. 1, 2018
Location	Poland
Headquarters	ul. Dunska 11
Employees	4
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.

Key trends

Past 5 years